It is an immunotherapy-based drug ... for the first-line treatment of primary advanced or recurrent endometrial cancer to improve survival. "With this FDA approval, Jemperli is now the only ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...

I want to move to a hotter topic in endometrial cancer, and that's really around immunotherapy. You gave the invited discussant presentation at the Society of Gynecologic Oncology (SGO ...

They’re often used with chemotherapy to treat advanced or recurrent cancer. Immunotherapy drugs approved to treat endometrial cancer are: Dostarlimab (Jemperli) Durvalumab (Imfinzi ...

In the phase III DUO-E trial among advanced endometrial cancer patients getting chemotherapy, adding the immunotherapy agent durvalumab with or without the PARP inhibitor olaparib (Lynparza ...

If you have recurrent endometrial cancer, your doctor will talk to you about your treatment options, including radiation, chemotherapy, immunotherapy, or sometimes surgery. (Photo Credit ...

and endometrial cancer" and can also be found in “cancers of the breast, prostate, bladder and thyroid.” The immunotherapy drug works by targeting cells with this mutation, as the ...

Gynecological cancers, including endometrial and cervical cancers, remain a leading cause of cancer deaths and a major challenge to women's health worldwide. Immunotherapy has greatly improved ...

About 16% of ovarian cancers and as much as 30% of endometrial cancers ... people are being diagnosed with cancer, Cercek said. The research also suggests that immunotherapy could possibly be ...

These immunotherapy drugs effectively remove the “brakes” that cancer cells place on the ... The drug is already approved for treating endometrial cancers with the same genetic mutation.

But she had immunotherapy treatment two years ago ... Only about 16% of ovarian cancer has it, while as much as 30% of endometrial cancer has the mutation, NBC News reported.